XiFin just shipped an AI agent that evaluates payor requirements, assembles supporting documentation, and submits appeals autonomously — built specifically for pharmacy medical billing. That's not a workflow enhancement. That's a reclassification of what appeals work actually is.
At NACDS Total Store Expo this week, XiFin introduced the Empower AI Appeals Agent as part of its broader Empower AI ecosystem. The announcement is targeted at retail and specialty pharmacies that are increasingly delivering services — immunizations, preventive care, specialty medication therapies — that bill under the medical benefit rather than the pharmacy benefit.
The product does four things that previously required a human:
That last step — autonomous submission — is the one worth flagging. Most AI tools in RCM still keep a human in the loop at the point of transmission. XiFin is positioning this as end-to-end agentic execution.
Pharmacy RCM used to be relatively contained: pharmacy benefit claims, adjudicated in real time, through PBMs. Denials existed, but the appeals workflow was narrower and more predictable.
That's changing fast. Two converging pressures are driving complexity into the pharmacy revenue cycle:
Specialty expansion. Many high-cost specialty therapies — oncology, immunology, rare disease — are covered under the medical benefit, not the pharmacy benefit. As pharmacies take on more specialty dispensing and administration, they inherit the full complexity of medical claims: authorization requirements, clinical documentation standards, payor-specific coverage policies, and denial rates that look nothing like traditional pharmacy claims.
Scope of practice expansion. The Main Street Pharmacy Access Act, currently moving through Congress, would expand reimbursement for pharmacist-delivered clinical services under Medicare. If it passes, pharmacies that have spent years building clinical capabilities — vaccination programs, chronic disease management, point-of-care testing — will suddenly have a medical billing surface that rivals some physician practices.
of pharmacies in XiFin's 2026 survey reported offering immunizations — the most widely delivered clinical service
increase in companion immunizations among pharmacies using XiFin's CareALERTS in 2025
Those immunizations are revenue. Revenue that requires clean medical claims. Claims that get denied. Denials that require appeals. Appeals that, until now, required staff time that most pharmacy operations don't have.
The word "agentic" gets used loosely in vendor marketing right now. In this context, it means something specific: the system doesn't just surface a recommendation — it executes the action. The agent reads the denial, determines the appropriate response, builds the package, and submits it without a human touching it.
That's a different risk profile than AI-assisted appeals, where a biller reviews the AI's draft before it goes out. Fully autonomous submission means the vendor is taking on accountability for submission accuracy in a way most RCM AI vendors have carefully avoided.
When an AI system autonomously submits appeals, the error cost changes. A missed coverage criterion or wrong documentation package doesn't just waste a biller's time — it creates a denial record with a payor, potentially flags the provider for audit patterns, and starts a clock on the appeal deadline. Buyers should ask specifically: what's the fallback when the agent gets it wrong?
That's not a reason to dismiss the product. It's the right question to ask before deploying it at scale. XiFin has clinical and payer data depth — they process medical billing across diagnostics, radiology, and specialty pharmacy — so they have a credible claim to the payor-specific coverage policy knowledge that makes autonomous appeals viable. The question is whether pharmacy-specific denial patterns are covered with the same depth.
Appeals automation has been a bottleneck in RCM AI deployment because it requires the highest-stakes decision-making: is the documentation sufficient, is the denial technically correct, what's the payor's actual adjudication behavior versus what's in the policy. These are judgment calls that most vendors have been reluctant to automate end-to-end.
XiFin moving to full submission automation in pharmacy signals that the underlying models — payor policy parsing, documentation adequacy scoring, coverage criteria matching — have matured enough that at least one major vendor is willing to own the outcome.
Expect competitors to respond. Waystar, Availity, and the major PM vendors with denial management modules are all in the same conversation with large health systems. If XiFin's pharmacy deployment shows clean outcomes data over the next 12–18 months, the pressure to match it in the hospital/physician billing space will accelerate.
For revenue cycle leaders watching this from the hospital or physician side, the near-term implication isn't "buy this product." It's a benchmark question: if agentic appeals submission is viable enough to ship in pharmacy medical billing today, what's the legitimate reason your appeals workflow still requires a dedicated FTE queue?
The answer may be that your payor mix, denial patterns, or documentation complexity genuinely require human judgment at the submission point. But if the answer is "we haven't evaluated it," the XiFin launch makes that a harder position to hold going into 2027 budget cycles.
XiFin's Empower AI Appeals Agent is a meaningful product launch, not a press release. Fully autonomous appeal submission in a high-complexity billing environment is a genuine capability milestone. The buy signal is strongest for specialty pharmacies with growing medical benefit exposure and limited appeals staffing. For the broader RCM market, it's the clearest signal yet that agentic execution — not just AI-assisted drafting — is becoming the baseline expectation for denial management automation.
Payor policy shifts, denial trends, vendor moves — before they hit your A/R. Free for revenue cycle teams.